Therapies targeting these immune pathways, including transforming growth factor-β2 (TGF-β2) and lactoferrin, show promise in preclinical models for mitigating inflammation and improving outcomes in infants with NEC.<h4>Conclusions</h4>Targeting myeloid cell immune responses represents a potential therapeutic strategy in NEC. The gene discussed is LTF; the disease is necrotizing enterocolitis.